Navigation Links
Drug resistance: 'Baby steps' can pay off big
Date:1/9/2013

HOUSTON -- (Jan. 9, 2013) -- Rice University scientists have found that mutations of small effect can turn out to be game changers in the bacterial fight against antibiotic drugs.

The discovery came during an exhaustive, three-year effort to create a mathematical model that could accurately predict how specific mutations allow bacteria like E. coli to adapt to antibiotics like minocycline. The findings are detailed in a Dec. 10 study in the Proceedings of the National Academy of Sciences.

"As biologists, we tend to focus on big effects that result from big changes, but this study shows that bacteria don't have to solve the problem of antibiotic resistance in one giant step," said Rice University biochemist Yousif Shamoo, the lead researcher on a new study. "We were surprised to see that small mutations could make a big difference. In some cases, we saw that minor molecular changes could boost resistance by as much as 500 percent."

Despite the remarkable success of antibiotics, bacterial infections remain a leading cause of death, and antibiotic resistance among bacterial pathogens is a significant threat to public health.

Shamoo, professor of biochemistry and cell biology and director of Rice's Institute of Biosciences and Bioengineering, said the study of antibiotic resistance offers opportunities to both examine complex cellular phenomena and address the "genotype to phenotype problem," one of modern biology's major challenges.

"We've sequenced hundreds of genomes, and we're finding that it's one thing to read the blueprint, and it's another thing to predict how the DNA in that blueprint will affect change in a living cell," Shamoo said.

Shamoo said that because a single antibiotic resistance gene can make big changes in whether a cell lives or dies, it is possible to make the connection between the gene and the cell's fitness to its environment.

To show that a mathematical model cou
'/>"/>

Contact: Jade Boyd
jadeboyd@rice.edu
713-348-6778
Rice University
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Grant funded to improve mothers nutrition before pregnancy and impact on baby
2. Eating well during pregnancy reduces babys obesity risk regardless of moms size
3. Male snails babysit for other dads
4. Lawson researcher sings the baby blues
5. A diet high in choline during pregnancy may mean less stress for baby
6. Warm, dry El Nino weather puts baby sea turtle at risk
7. A new method detects traces of veterinary drugs in baby food
8. U of I study: Lose body weight before gaining baby weight
9. Flying jewels spell death for baby spiders
10. Following in Marie Curies footsteps
11. Synthetic diamond steps closer to next generation of high performance electrochemical applications
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug resistance: 'Baby steps' can pay off big
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/15/2014)... Alt will be awarded the 44th Rosenstiel Award for ... his pioneering research exploring the mechanisms of genomic instability ... cells. Alt is the second alumnus to win the ... Prize in 2003. , Alt is the Charles A. ... Harvard Medical School and an investigator at the Howard ...
(Date:10/14/2014)... N.C. – Like discriminating thieves, prostate cancer tumors scavenge ... the body. But such avarice may be a fatal ... a way to kill prostate cancer cells by delivering ... selectively destroys the diseased cells brimming with the mineral, ... uses two drugs already commercially available for other uses, ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
... Rainmakers, Inc., an intellectual property holding company and advanced ... its "stealth" mode and is prepared to actively commercialize ... security offerings. , During the past four years, the ... develop and deploy a series of core--but expandable--technologies built ...
... up 45 percent of blood, normally take the shape of ... can sometimes deform into an asymmetrical slipper shape. A ... flow might be responsible for this deformation, as well as ... could help understand the mechanisms involved in arterial disease and ...
... CAMDEN Contrary to a national trend, more and ... major in math and science. Thanks to a $307,277 ... students in the sciences at RutgersCamden will receive unprecedented ... of their degrees. Through a new RutgersCamden program ...
Cached Biology News:Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3NSF grant supports Rutgers-Camden program for science majors 2NSF grant supports Rutgers-Camden program for science majors 3
(Date:10/20/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four ... million and provides a good start to Q4.  The orders are ... and one in the Middle East . ... said Peter Bruijns , President & CEO. "Total bidding activity ... they have been for any complete year since the company has ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report ... with analysis and forecast of revenue. This market is ... $208 million by 2019, at a Compound Annual Growth ... Browse through the TOC of the Asia-Pacific Speech Analytics ... analysis provided. It also provides a glimpse of the ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... PARIS and LAUSANNE, Switzerland, September 7 ... Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical,group of ... prescription drugs that,target unmet medical needs, announced today ... granted an exclusive worldwide license to develop,and commercialise ...
... manufacture hydroxyapatite (HA) could be used to make stronger, ... University of Birmingham this week (7-10 September) presented work ... University, Edinburgh. Using Serratia bacteria, the ... surfaces such as titanium alloy, polypropylene, porous glass and ...
... Sept. 6 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... biotechnology company,focused on researching, developing, manufacturing and marketing,biopharmaceutical ... of,shareholders of 3SBio Inc. will be held on ... No.3 A1, Road 10, Shenyang Economy & Technology ...
Cached Biology Technology:Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 2Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 3Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 4Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 53SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009 2
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
... PAGE Cleavable ICAT Reagent ... Protein ID and Quantitation ... Electrophoresis (PAGE), isotope-coded affinity ... technology to facilitate the ...
Supplemental reagent for annexin V assay....
Biology Products: